A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.

Abstract

Determination of the maximum tolerated dose (MTD) is the main objective of phase I trials. Trials are typically carried out with restricted sample sizes. Model-based approaches proposed to identify the MTD (including the Continual Reassessment Method or CRM) suppose a simple model for the dose-toxicity relation. At this early stage of clinical development… (More)
DOI: 10.1002/sim.3682

Topics

Cite this paper

@article{Paoletti2009ACO, title={A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.}, author={Xavier Paoletti and A. Kramar}, journal={Statistics in medicine}, year={2009}, volume={28 24}, pages={3012-28} }